Clinuvel Pharmaceuticals has submitted a request to sell NEURACTHEL® Instant in Europe, aiming to launch in three main markets.

CUVL · Clinuvel Pharmaceuticals

The AI's read

For Clinuvel, a review shared across several EU countries could open a route into markets where ACTH supplies are reported short. That creates a sales opportunity, not sales already won. Regulators may take about 300 days to decide, and approval is not assured.